K. PengsaaK. Na-BangchangK. LimkittikulK. KabkaewK. LapphraC. SirivichayakulP. WisetsingC. Pojjaroen-AnantP. ChanthavanichA. SubchareonMahidol UniversityThammasat University2018-07-242018-07-242004-06-01Annals of Tropical Medicine and Parasitology. Vol.98, No.4 (2004), 349-357000349832-s2.0-3142516059https://repository.li.mahidol.ac.th/handle/123456789/21380The pharmacokinetics of albendazole/albendazole sulphoxide and praziquantel were investigated in Thai children with Giardia infection. Twenty school-age children were randomly allocated to receive either a single oral dose of albendazole (400 mg/child) or the same dose of albendazole given concurrently with a single oral dose of praziquantel (20 mg/kg). The concentrations of albendazole/albendazole sulphoxide and praziquantel in plasma samples, collected at intervals in the first 24 h post-treatment, were then quantified using HPLC with ultra-violet detection. No significant pharmacokinetic interaction between the albendazole and praziquantel was demonstrated. For albendazole sulphoxide, the active metabolite of albendazole, there was marked inter-individual variation in the maximum plasma concentration and the 'area under the curve'. The pharmacokinetics of albendazole sulphoxide were similar whether albendazole was given alone or in combination with praziquantel.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1179/000349804225003398